The functional interactions between supraspinal p, and 8 receptors were characterized in the mouse using p, receptor-selective antagonists. The effects of pretreatment with the p, opioid antagonists, /~-funaltrexamine (/'/-FNA) and naloxonazine on the modulation of morphine antinociception by the 8 agonists [D-PenZ,D-PenS]enkephalin (DPI)PE) and [D-AlaZ,MetS]enkephalinamide (DAMA) were studied. When co-administered in the same i.c.v. injection, a sub-antinociceptive dose of DPDPE consistently and significantly increased the antinociceptive potency of morphine in control animals, while a sub-effective dose of DAMA decreased morphine antinociception: both the respective increase and the decrease of morphine potency by DPDPE and DAMA had been previously shown to be blocked by ICI 174,864, a 8 antagonist. Pretreatment of mice with the non-equilibrium p. antagonist /'/-FNA 4 h prior to testing, a pretreatment which had no effect on i.c.v. DPDPE or DAMA antinociception, prevented the modulation of morphine antinociception by both DPDPE and DAMA. Pretreatment with the long acting pq antagonist naloxonazine, 24 h prior to testing, failed to affect the modulation of morphine antinociception by either DPDPE or DAMA: such a pretreatment had no effect on the antinociceptive effects of DPDPE or DAMA when given alone. These results provide further support for the concept of a functionally coupled p.-6 receptor complex which is sensitive to antagonism by fl-FNA, but not naloxonazine, and support the notion that subtypes of opioid p~ and 8 (i.e. complexed and non-complexed) receptors may exist.
!. Introduction
focus of a great deal of research. Of the effects studied, opioid-induced antinociception remains The suggestion of multiple opioid receptor subat the forefront of interest and relevance. Recent types has been supported by a great deal of eviinvestigations, which used heat as the noxious dencc obtained in vitro (Lord et al., 1977; Gioanstimulus, have demonstrated that supraspinal nini et al., 1985; Cho et al., 1986) and in vivo opioid-induced antinociception in mice can be (Martin et al., 1976) . Nevertheless, the correlation mediated by both 8 (Porreca et al., 1984 : Heyman of opioid-induced effects with specific receptor : Mathiasen et al., 1987 . subtypes has been difficult and continues to be the 1987: Takemori and Portoghese, 1987) and /x opioid receptors. In addition to the direct role played by the 6
Correspondence to: F. Porreca Takemori, 1979: Barrett the assay medium (Bowen et al., 1981 : Rothman and Vaught. 1982 . Conet al.. 1984b) : (by the ability of the site directed versely, sub-antinociceptive doses of [MetS] enacylating agent FIT enkephalin analogs significyanato)phenylethyl-4-piperadinyl]propanamide)-cantly decrease i.c.v, morphine antinociceptive H('I to unmask lower affinity [~H]I)ADLE bindpotency (l.ee et al.. 1980 (l.ee et al.. : Vaught et al., 1982 .
ing sites but not p. sites (Rothman et al.. 1985b ): Evidence that these modulatory effects are media-(c) the observation that the i.c.v, administration of ted via a 8 receptor includes the recent observafl-funaltrexamine (fi-ENA, Portoghcse et al.. 1980 ) tions that the 6-selective antagonist ICI 174.864
to rats 24 h prior to preparation of brain mere- (Cotton et al.. 1984) prevented both the increase branes results in an approximately 6()~ decrease (Heyman et al.. 1986b; 1989) (Rothman berg et al.. 1983 : Porreca et al.. 1984 : James and et al.. 1984a : 1986 : 1989 (Rothman et al., 1985a.c (Rothman et al., 1986; 1989 , 1980) . Ad- Fig. 1 . Time-response curve for i.c.v. DAMA (1.7 nmol) antiditionally, in an attempt to gain further insight nociception in the mouse. Data are means and S.E. into the nature of the ~t.~ and ~,~ sites, naloxonazine (Hahn et al., 1982) , an antagonist of the putative ~ receptor was (vehicle) or fl-FNA (18 nmol) 4 h prior to agonist studied, administration, similar to the procedure described by Ward et al. (1982) . In studies with naloxonazine, each mouse received a single subcutaneous 2. Materials and methods (s.c.) injection of distilled water (vehicle) or naloxonazine HCI (35 mg/kg) 24 h prior to testing as
Animals described by Ling et al. (1986).
Male, ICR mice (20-30 g, Harlan, Indianapolis,
Antinociceptwe testing
IN) were used for all experiments. Animals were kept in groups of five in a temperature-controlled Antinociceptive responses were determined usroom with a standard 12 h light/dark cycle (lights ing warm (55°C) water as the nociceptive stimon 07:00 h). Food and water were continuously ulus where the latency to tail withdrawal was available, taken as the endpoint (Janssen et al., 1963) . Prior to agonist administration, the tail of each mouse
h!jection techniques
was immersed in the water and the latency to a rapid flick recorded. Animals not flicking their Compounds were delivered into the lateral tails within 5 s were eliminated from the study. cerebral ventricle using a modification of the This procedure was repeated 20 rain after i.c.v. method of Haley and McCormick (1957) as previadministration of morphine, DPDPE and DAMA; ously described (Porreca et al., 1984) . Briefly, the this was the time of peak agonist effect as demice were lightly anesthetized with ether, an incitermined from time-response curves (morphine and sion was made in the scalp and bregma located. DPDPE, Heyman et al., 1986a ; DAMA, fig. 1 ). The injections were made 2 mm caudal and 2 mm Animals not flicking their tails within 15 s were lateral to bregma at a depth of 3 mm using a removed from the nociceptive stimulus and asHamilton (Reno, NV) microliter syringe with a 26 signed a maximal score of 100% in order to avoid gauge needle. All i.c.v, injections were made in a tissue damage. Antinociception was expressed as: volume of 5 v,l.
% antinociception = 100 × (test latency -control latency)/(15 s-control latency). fig. 3 ), pretreated mice, program of Tallarida and Murray (1986) (procedoses of DPDPE and DAMA which produced dure 8) in control, fl-FNA and naloxonazinc prebarely detectable antinociception (0-5%) in the treated mice. A minimum of 10 mice were studied respective groups were chosen by downward exat each dose level. Modulatory effects of DPDPE and DAMA on morphine antinociception were trapolation of the dose-response line. In order to identified using a Student's t-test for grouped data. determine if DPDPE and/or DAMA were capable of modulating i.c.v, morphine antinociception
The data are presented as the mean and the error in animals pretreated with ,8-FNA or naloxonabars arc the S.E. zine, the 6 agonists were co-administered in the same i.c.v, injection with morphine as previously described by Vaught el al. (1982) Ward and Takemori, 1983; Heyman et al., 1987) , Naloxonazine pretreatment does not affect the attenuation of morphine antin(x:iception produced by DAMA. Data are means and S.E. and asterisks indicate a significant difference from controls (P < 0.005, Student's t-test).
tion of antinociception using receptor selective formulation of the following testable prediction: if antagonists. Doses of the 8 agonists DPDPE and the modulatory effects of sub-antinociceptive do-DAMA which produced no significant antinocises of 6 agonists on morphine antinociception are ception when given alone were found to increase mediated via an opioid receptor complex, then and decrease the potency of i.c.v, morphine in pretreatment with ,8-FNA should prevent the abilproducing antinociception, respectively, in agreeity of 8 agonists to modulate morphine antinociment with previous studies (Lee et al., 1980 : ception, Vaught et al., 1982 Porreca et al., 1987; Heyman The present study demonstrates that pretreatet al., 1986b: 1989) . These modulatory effects have ment with/3-FNA abolishes both the increase and previously been shown to be due to an interaction decrease of morphine potency associated with of the agonists with the 8 receptors as the 8-selec-DPDPE and DAMA. respectively, a finding which tive antagonist ICI 174,864 (Cotton et al., 1984) might be interpreted as supporting the concept of prevented both the increase (Heyman et al., 1986b;  functional uncoupling of the /~-8 complex given 1988b) and decrease (Heyman et al., 1986b) ICI 154.129 (Shaw et al., 1982) , onist does not inhibit 6 .... binding in rat brain respectively, compounds which do not directly membrane preparations (Rothman et al., 1984a;  antagonize morphine tail withdrawal antinocicep1987a,b), nor does it block the antinociceptive tion in control mice, significantly antagonize effects of 8 agonists given i.c.v, in mice (Heyman morphine antinociception in ,8-FNA-pretreated et al., 1987) . Thus, the ability of/3-FNA to premice. Modulation by 6 agonists, therefore, would vent the effects of ICI 154,129 was suggested to be not be possible if both agonists were acting at the the result of an alteration in the p,-6 receptor same receptor (6,,(,x) . Furthermore, the competicomplex (Holaday and D'Amato, 1983 ; D'Amato tive interactions of p, and 6 ligands at this binding and Holaday, 1984) . Additionally, i.c.v, adminissite (6, , , ., ) in vitro are consistent with the observatration of/3-FNA to rats 18-24 h prior to preparations in vivo which demonstrate that DPDPE and tion of brain membranes has been demonstrated DAMA do not modulate morphine antinocicepto lead to a selective alkylation of the opioid tion when morphine acts at the 6,~ site. receptor complex which was reflected by a subFurther attempts to characterize the /.t-6 funcstantial decrease in the Bma ~ of the 6~,~ binding site, tional interaction were made using the long-lasting while the binding of [3H]DADLE to the 6r,~x site proposed ,% antagonist naloxonazine. Naloxonawas not significantly altered (Rothman et al.. 1986;  zine pretreatment had no effect on i.c.v. DPDPE 1989). This apparent selective effect of ,8-FNA on antinociception in agreement with previous studies the opioid receptor complex in vivo allowed the where this antagonist neither blocked i.c.v. DPDPE antinociception in the mouse (Heyman et al., 1988) DAGO antinociception by DPDPE, therefore, is or rat (Ling el a[,, 1986) , nor altered binding of not directly in accord with the concept that the p.~., DPDPE in rat brain preparations (Clark et al., receptor is the sole site for the mediation of p. 1986). Similarly, naloxona~,.ine pretreatment had antinociception. It is also important to note that no effect on i.c.v. DAMA antinociception (present while naloxonazine pretreatment has previously study). In contrast to the lack of effect of nalobeen shown to antagonize both i.c,v, morphine xonazine on DPDPE and DAMA antinociception, and DAGO antinociception (Heyman et al,. 1988 ), this antagonist exhibited the expected long-lasting this antagonist had no effect on the ability of blockade of i.c.v, morphine antinociception in the DPDPE or I)AMA to modulate morphine antimouse in agreement with previous studies in this nociception. The lack of effect of naloxonazine oq species (Heyman et al., 1988) as well as in the rat the modulation of morphine antinociception cou- (Ling et al.. 1986 ). Potentiation and attenuation of pied with the antagonism of both morphine and morphine antinociception by DPDPE and DAMA.
DAGO antinociception by naloxonazine again respectively, were still evident in mice that resuggests a discrepancy with the concept that anticeived naloxonazine treatment prior to testing, nociception is mediated solely at thc p., site. Various interpretations might be made from these Although reasons which might account for these findings. For example, naloxonazine might alter discrepancies can be formulated, it seems clear the conformation of the receptor complex in such that further experiments are needed to resolve the a way that morphine binds with lower affinity, inconsistencies noted above. Although inconthus reducing the potency, but leaving the modsistencies do exist as to the identity of the specific ulatory mechanisms intact. As the mechanism of site where p. agonists act to produce their antiaction for the long-lasting antagonism associated nociceptive effects, it is important to note that the with naloxonazine is not well understood, condifferential antagonism of the modulation obtinued action of morphine may be due to incomserved with /~-FNA and naloxonazine, nevertheplete blockade of ~t~ receptors. Alternatively, it is less continues to support the concept of p. receptor also possible that the p, receptors in the receptor subtypes. complex are naloxonazine insensitivity (i.e.. p,:).
Although the existence of such a complex reAs is often the case, the present findings in vivo mains tentative, p,-8 interactions have been demare not in complete agreement with hypotheses onstrated for other endpoints from studies in vivo drawn from findings in vitro. Based on evidence and in vitro. In addition to antinociception, p.-8 from binding studies with fl-FNA, one would interactions have also been observed in vivo in the predict that all # agonists act at the P-c, receptor reversal of endotoxic shock (Holaday and to produce their antinociception (Rothman et al., D'Amato, 1983" D'Amato and Holaday, 1984; 1986; 1987a : 1989 . It has been shown previously Holaday et al., 1985 Holaday et al., , 1986 ) and the elevation of (Heyman et al., 1989) , however, that while morflurothyl seizure threshold (Holaday et al., 1985) . phine antinociception is potentiated by DPDPE,
The finding that ,8-FNA, but not naloxonazine, the antinociceptive effects of the p, agonist DAGO affected the 6 modulation of g, antinociception (Handa et al., 1981) are not. a finding which provides support in vivo for the concept that suggests that morphine and DAGO may act at morphine antinociception is mediated through this two distinct p, receptors (p,~.~ and p, ..... respeccomplex, that 8 modulation of morphine antitively) to produce their antinociceptive effects, nociception occurs through this complex and that Although morphine and DAGO antinociception the p, site in the receptor complex is naloxonazine are both antagonized by pretreatment with/3-FNA insensitive. Thus. in addition to playing a direct (Heyman et al., 1987) , a finding in agreement with role in the production of antinociception, the enbinding studies and the above prediction, only kephalins may also play a modulatory role in morphine antinociception is modulated by DPDPE antinociception by acting in an opioid (p~-~) recep- (Heyman et al., 1989) . The lack of modulation of tor complex.
